Joyce O’Shaughnessy, MD

Articles

Best Practices in Managing Patients on Capivasertib

November 4th 2024

Panelists discuss the key advice they would offer to fellow physicians, nurse practitioners, advanced practice providers, and pharmacists involved in the care of patients on capivasertib, emphasizing best practices for patient management and communication.

Managing Capivasertib Side Effects: Strategies for Educating, Monitoring, and Addressing Rash and Hyperglycemia

November 4th 2024

Panelists discuss their approach to monitoring and managing hyperglycemia in patients receiving capivasertib and providing education about it, including when to involve endocrinology and how management strategies may differ for patients with preexisting diabetes.

Adverse Event Management: Strategies for Reducing Diarrhea Risk in Capivasertib Therapy

October 28th 2024

Panelists discuss the strategies they employ to manage adverse events in patients starting capivasertib, including minimizing the risk of diarrhea through dietary considerations and patient education, as well as approaches for monitoring and managing rash associated with the treatment and providing education about it.

Clinical Experience with Capivasertib

October 28th 2024

Panelists discuss their clinical experiences with capivasertib, focusing on patient tolerability and the management of adverse effects associated with this targeted therapy.

Overview of the CAPItello-291 Trial

October 21st 2024

Panelists discuss the findings of the CAPItello-291 trial, which investigated capivasertib combined with fulvestrant in advanced hormone receptor–positive, HER2-negative breast cancer, leading to its approval in November 2023 and highlighting its potential as a new targeted therapy option in the second-line setting due to the prevalence of PIK3CA, AKT1, and PTEN alterations.

Role of PI3K/AKT/PTEN Pathway in HR+/HER2- Advanced Breast Cancer

October 21st 2024

Panelists discuss how aberrations in the PI3K/AKT/PTEN pathway drive treatment resistance and disease progression following first-line therapy in hormone receptor–positive, HER2-negative advanced breast cancer, emphasizing the critical role of repeat biomarker testing to guide ongoing treatment strategies and enhance patient outcomes.

First-Line Treatment Strategies for HR+/HER2- Advanced Breast Cancer

October 14th 2024

Panelists discuss how to approach selecting first-line treatment options for hormone receptor–positive, HER2-negative advanced breast cancer by providing an overview of standard-of-care options and highlighting the primary considerations that guide treatment selection.

Insights on Biomarker Testing in HR+/HER2- Advanced Breast Cancer

October 14th 2024

Panelists discuss how biomarker testing plays a critical role in hormone receptor–positive, HER2-negative advanced breast cancer, emphasizing the timing of testing, the relevance of specific genomic assays, and the significant impact on prognosis and treatment decisions.

Clinical Impact of Subcutaneous Fixed-Dose Pertuzumab – trastuzumab-hyaluronidase in HER2+ Breast Cancer

July 1st 2024

Breast cancer specialists outline their institution’s practices regarding the choice between subcutaneous fixed-dose pertuzumab – trastuzumab-hyaluronidase and intravenous pertuzumab and trastuzumab.

Neoadjuvant Treatment Options in HER2+ Early Breast Cancer

June 24th 2024

Ian Krop, MD, PhD, outlines his institution’s approach to utilizing neoadjuvant therapy in patients with HER2+ early breast cancer, and Melinda Telli, MD, discusses the role of surgery.

Challenges in Diagnosing HER2+ Breast Cancer

June 24th 2024

A panel of experts on breast cancer provide insights on challenges encountered during the diagnosis of HER2+ early breast cancer and discuss the role of immunohistochemistry and FISH testing.

Ongoing Studies in Genomic Testing for Breast Cancer

February 27th 2024

Closing their discussion, experts share ongoing studies utilizing genomic testing for patients with breast cancer.

Reflecting on Genomic Testing in Practice for Breast Cancer

February 27th 2024

Joyce O’Shaughnessy, MD and Erin Cobain, MD, offer their reflections of genomic testing in breast cancer and its impact on clinical practice.

Racial Disparities and Genomic Testing for Breast Cancer Patients

February 20th 2024

Dr O’Shaughnessy and Dr Cobain review growing discussions from SABCS 2023 surrounding the impact of racial disparities and genomic testing for breast cancer patients.

Real-World Evidence in Genomic Testing from SABCS 2023

February 20th 2024

Experts in breast cancer outline data presented at SABCS 2023, focusing on real-world evidence for genomic assays used in practice.

Exploring Multigene Genomic Assays in High-Risk BC Patients

February 13th 2024

Dr. O’Shaughnessy details the genomic assay MammaPrint and how it compares to other multigene assays used in practice, highlighting the MINDACT and TAILORx trials.

FLEX Trial: Genomic Testing of HER2 Status in ER+/HER2-Breast Cancer

February 13th 2024

Expert oncologists discuss genomic testing for patients with HER2-low breast cancer, noting the FLEX trial of MammaPrint and BluePrint.

Clinical Considerations of Genomic Testing in Early-Stage Breast Cancer

February 8th 2024

A discussion on clinical considerations for genomic testing in patients with early-stage breast cancer.

MammaPrint: A 70-Gene Signature Test for Patient with Breast Cancer

February 8th 2024

Dr. O’Shaughnessy introduces MammaPrint and BluePrint, discussing their role in genomic testing for patients with breast cancer.

Overview of Genomic Assays for Early-Stage Breast Cancer

February 8th 2024

A comprehensive overview of genomic assays conducted for patients with early-stage breast cancer including MammaPrint, BluePrint, Oncotype DX.